Intestinal epithelial cells (IECs) play an important role as barrier and as cellular factories in charge of absorbing and processing dietary nutrients, as well as the secretion of defense molecules and the orchestration of immune responses. Alterations in the normal function of IECs contribute to pathologies like inflammatory bowel diseases (IBD). Importantly, patients with IBD are at an increased risk for colorectal cancer (CRC), which is one of the most prevalent neoplasias among the US population. Recent studies have shown the critical role of Paneth cell dysfunction in controlling IEC survival and the etiopathogeneis of intestinal inflammation. Therefore, understanding how different signaling cascades control intestinal homeostasis is a fundamental question in biology with potential therapeutic implications for IBD and CRC. We will address these questions in the context of PKC?/?. Our preliminary data demonstrate that the selective inactivation of PKC?/? in IECs results in the loss of Paneth cells, which provokes the break of the intestinal barrier, dysbiosis, intestinal inflammation and increased tumorigenesis. Importantly, PKC?/? expression decreases with progression in CD and it predicts poor survival in CRC. Of note, this Paneth cell defect is associated with increased crypt apoptosis, JNK activity and autophagy in PKC?/?-deficient IECs. Our hypothesis is that PKC?/? is an essential regulator of autophagy and cell death in intestinal cell homeostasis and inflammation-driven tumorigenesis. In this proposal we will address the following fundamental questions: (1) What is the role in vivo of JNK activation by PKC?/? deficiency in increased apoptosis of IECs and intestinal inflammation and tumorigenesis? (2) What are the mechanisms whereby PKC?/? inhibits JNK activity? (3) Is enhanced autophagy in PKC?/?-deficient IECs a survival mechanism in vivo to antagonize the increased JNK and apoptosis promoted by the loss of PKC?/? and to prevent intestinal inflammation and tumorigenesis? (4) What are the mechanisms whereby PKC?/? represses autophagy? Questions 1 and 2 will be answered by the experiments described in Aim 1; and questions 3 and 4 will be answered by the experiments described in Aim 2. This proposal will unveil a new paradigm whereby PKC?/? controls IEC apoptosis and autophagy and their role in intestinal homeostasis and inflammation-driven tumorigenesis, opening possibilities for new therapies.

Public Health Relevance

Dysfunction of intestinal cell homeostasis contributes to the pathogenesis of chronic inflammatory bowel disease. The scope of this study is to investigate the role and mechanism of action of PKC?/? as an essential regulator of autophagy and cell death in intestinal cell homeostasis and inflammation-driven tumorigenesis. This proposal will have a great impact in advancing our understanding of the signaling mechanisms that govern intestinal inflammation and cancer, and for the design of new and more selective therapeutic strategies for its treatment

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA207177-02
Application #
9458144
Study Section
Cellular Signaling and Regulatory Systems Study Section (CSRS)
Program Officer
Salnikow, Konstantin
Project Start
2017-03-21
Project End
2022-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sanford Burnham Prebys Medical Discovery Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Shelton, Phillip M; Duran, Angeles; Nakanishi, Yuki et al. (2018) The Secretion of miR-200s by a PKC?/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer. Cell Rep 23:1178-1191
Nakanishi, Yuki; Duran, Angeles; L'Hermitte, Antoine et al. (2018) Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance. Immunity 49:1132-1147.e7
Reina-Campos, Miguel; Shelton, Phillip M; Diaz-Meco, Maria T et al. (2018) Metabolic reprogramming of the tumor microenvironment by p62 and its partners. Biochim Biophys Acta Rev Cancer 1870:88-95